This article was originally published in The Gray Sheet
Expects flat net earnings for the second half of the fiscal year compared to the same period last year, the firm says March 15. Datascope explains that hospitals are reducing purchases of its intra-aortic balloon catheters to lower inventories in response to potential health-care policy changes. The firm also notes that its intra-aortic balloon pump distributor in Japan is forecasting reduced purchases for the balance of the fiscal year.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.